NCCN Recommends Zanubrutinib as First-Line, Se... - CLL Support
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL
You need to be a member of this community to see this post.
Read more about...
36 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors
with CLL/SLL who develop resistance to BTK inhibitors. Please see article at:...
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
nic-lymphocytic-leukemia/zanubrutinib-bests-bendamustine-rituximab-cll-sll-previously-untreated/
Ibrutinib Slow but steady foreward movement.
called Bruton's tyrosine kinase (BTK) inhibitors. Data suggest ibrutinib covalently bonds to BTK in...
CALQUENCE gets FDA approval for treating CLL
The latest approval for Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor, was...
B-PLL: Ibrutrinib Monotherapy or Obinutuzumab (aka Gazyva) & Venetoclax Combination as first-line treatment for transformed CLL
unmutated, 17P undeleted) but is IGHV unmutated.
We have two CLL experts who propose different...
Related Posts
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
Ibrutinib, Acalabrutinib, or Zanubrutinib 
Australian current treatment legislation
